✦ LIBER ✦

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

✍ Scribed by Mita, Monica M.; Joy, Anil A.; Mita, Alain; Sankhala, Kamalesh; Jou, Ying-Ming; Zhang, Da; Statkevich, Paul; Zhu, Yali; Yao, Siu-Long; Small, Karen; Bannerji, Rajat; Shapiro, Charles L.

Book ID: 122193682
Publisher: CIG Media Group, LP.
Year: 2014
Tongue: English
Weight: 369 KB
Volume: 14
Category: Article
ISSN: 1526-8209
DOI: 10.1016/j.clbc.2013.10.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase 2 study of the cyclin-d

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

✍ Stephenson, Joe J.; Nemunaitis, John; Joy, Anil A.; Martin, Julie C.; Jou, Ying- 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 579 KB

Phase III randomized trial of sunitinib

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

✍ Carlos H. Barrios; Mei-Ching Liu; Soo Chin Lee; Laurence Vanlemmens; Jean-Marc F 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 289 KB

Phase I Trial of the Cyclin-Dependent Ki

Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Docetaxel in Patients With Metastatic Breast Cancer

✍ Nahta, R. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Phase II, double-blind, randomized trial

Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy

✍ Mark Clemons; Anil A. Joy; Radhi Abdulnabi; Mauricio Kotliar; Jodi Lynch; Johan 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 317 KB

Anti-tumor activity of capecitabine and

Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial

✍ Bojana Pajk; Tanja Cufer; Peter Canney; Paul Ellis; David Cameron; Emmanuel Blot 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 139 KB

A randomized, phase II, dose-finding stu

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

✍ Olivier Rixe; Sandra X. Franco; Denise A. Yardley; Stephen R. Johnston; Miguel M 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 367 KB